[1] SHAFFER B C,GILLET J P,PATEL C,et al.Drug resistance:still a daunting challenge to the successful treatment of AML.Drug Resistance Updates,2012,15(1-2):62-69.
[2] LALLEMAND-BREITENBACH V,ZHU J,CHEN Z,et al.Curing APL through PML/RARA degradation by As2O3.Trends in Molecular Medicine,2012,18(1):36-42.
[3] FANG J,CHEN S J,TONG J H,et al.Treatment of acute promyelocytic leukemia with ATRA and As2O3:a model of molecular target-based cancer therapy.Cancer Biology & Therapy,2002,1(6):614-620.
[4] 贺白,顾伟英,曹祥山,等.急性早幼粒细胞白血病患者早期死亡的临床分析[J].现代医学,2011,39(2):169-172.
[5] 蔡倩,徐酉华,刘筱梅,等.HSP90β在ATRA诱导的白血病细胞株HL60耐药中的作用研究[J].重庆医科大学学报,2010,35(11):1658-1661.
[6] 薛芳,成志勇,杨琳,等.白血病耐药细胞系U937/ADR的建立及其生物学性状[J].中国生物工程杂志,2009,29(7):17-21.
[7] 陈新峰,杨菁.用MTT法进行白血病体外药物敏感性检测的临床意义[J].福建医科大学学报,2009,43(2):169-171,177.
[8] 苏祖禄,苏海,张毅,等.脑胶质瘤化疗药物的体外敏感性试验研究[J].第三军医大学学报,2013,35(13):1420-1423.
[9] SANZ M A,LO-COCO F.Modern approaches to treating acute promyelocytic leukemia.Journal of Clinical Oncology,2011,29(5):495-503.
[10] CORNELL R F,PALMER J.Adult acute leukemia.Disease-a-month :DM,2012,58(4):219-238.
[11] ARTEAGA M F,MIKESCH J H,QIU J,et al.The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia.Cancer Cell,2013,23(3):376-389.
[12] 陈赛娟.白血病发病原理和靶向治疗研究——从急性早幼粒细胞到其他类型白血病[J].中华血液学杂志,2010,31:3-6.
[13] 张南文,许建华.人结肠癌耐药细胞系SW480/L-OHP的建立及其耐药机制初探[J].福建医科大学学报,2013(4):228-231. |